1 to 4 of 4 literature results

• Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis.

  Selective progesterone receptor modulators (SPRMs) represent a new class of progesterone receptor ligands. SPRMs exert clinically relevant tissue-sele…

  Authors: Kristof Chwalisz, Maria Claudia Perez, Deborah Demanno, Craig Winkel, Gerd Schubert, Walter Elger

  Source: Endocrine reviews. 2005 May

  View Full Text

• Therapeutic potential for the selective progesterone receptor modulator asoprisnil in the treatment of leiomyomata.

  Asoprisnil is a novel selective progesterone receptor modulator that exhibits partial agonist and antagonist activities in animals and humans. It demo…

  Authors: Kristof Chwalisz, Deborah DeManno, Ramesh Garg, Lois Larsen, Cynthia Mattia-Goldberg, Therese Stickler

  Source: Seminars in reproductive medicine. 2004 May

  View Full Text

• Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy.

  Asoprisnil is a novel selective steroid receptor modulator that shows unique pharmacodynamic effects in animal models and humans. Asoprisnil, its majo…

  Authors: Deborah DeManno, Walter Elger, Ramesh Garg, Ronald Lee, Birgitt Schneider, Holger Hess-Stumpp, Gerd Schubert, Kristof Chwalisz

  Source: Steroids. 2003 Nov

  View Full Text

• Selective progesterone receptor modulator asoprisnil induces endoplasmic reticulum stress in cultured human uterine leiomyoma cells.

  A recent clinical trial (Chwalisz K, Larsen L, Mattia-Goldberg C, Edmonds A, Elger W, Winkel CA. Fertil Steril 87: 1399-1412, 2007) has demonstrated t…

  Authors: Qin Xu, Noriyuki Ohara, Jin Liu, Koji Nakabayashi, Deborah DeManno, Kristof Chwalisz, Shigeki Yoshida, Takeshi Maruo

  Source: American journal of physiology. Endocrinology and metabolism. 2007 Oct

  View Full Text